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Abstract
Within drug development and pre-clinical trials, a common, significant and poorly understood event is the development of drug-
induced lipidosis in tissues and cells. In this manuscript, we describe a mass spectrometry imaging strategy, involving repeated
analysis of tissue sections by DESI MS, in positive and negative polarities, using MS and MS/MS modes. We present results of
the detected distributions of the administered drug, drug metabolites, lipid molecules and a putative marker of lipidosis, di-
docosahexaenoyl (22:6)-bis(monoacylglycerol) phosphate (di-22:6-BMP). A range of strategies have previously been reported
for detection, isolation and identification of this compound, which is an isomer of di-docosahexaenoic (22:6 n-3)
phosphatidylglycerol (di-22:6 PG), a commonly found lipid that acts as a surfactant in lung tissues. We show that MS imaging
using MS/MS can be used to differentiate these compounds of identical mass, based upon the different distributions of abundant
fragment ions. Registration of images of these fragments, and detected drugs and metabolites, is presented as a new method for
studying drug-induced lipidosis in tissues.
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Introduction
Mass spectrometry imaging (MSI) maps the spatial distribu-
tion of hundreds to thousands ofmolecules from a sample. It is
frequently used in drug pharmacokinetics and toxicology to
study the spatial distribution of drugs and metabolites in thin
tissue sections [1, 2]. In addition to being able to measure
drugs and exogenous metabolites in tissue, MSI can also be
used to image endogenousmetabolites, proteins or lipids with-
in a tissue [3, 4]. Within drug development and pre-clinical
trials, a common, significant and poorly understood barrier to
success is the development of lipidosis in tissues and cells as a
result of administered treatments. A deeper understanding of
lipid changes occurring as a result of drug dosing will allow
better selection of compounds for pre-clinical trials, and thus
decrease the number of animals required. Amiodarone is a
good model drug compound to study these effects, as it and
its metabolite, desethylamiodarone, are readily detected by
MSI in drug-treated mice [5] and oral dosing of amiodarone
has been shown to induce pulmonary lipidosis, along with
other adverse toxicological effects [6]. One previously report-
ed putative marker of lipidosis is an increase in di-
docosahexaenoyl (22:6)-bis(monoacylglycerol) phosphate
(di-22:6-BMP), a lipid species associated with drug-induced
lipidosis found within lysosome and endosomes [7]. Other
amiodarone-induced lipid alterations have also been studied
by MALDI MSI by Kashimura et al. primarily focused on
changes in phosphocholine lipids [8]. They showed that in
addition to di-22:6-BMP, amiodarone also increases levels of
phosphocholine lipids in lung, spleen and lymph node tissues.
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Additionally, the metabolic pathway of amiodarone has been
well-studied and characterised [9]. The lipidosis biomarker di-
22:6-BMP has also been associated with other adverse effects,
such as cerebral ischaemia which has been observed by DESI
and MALDI MSI in negative ion mode [10]. One of the sig-
nificant challenges associated with analysing di-22:6-BMP is
that it is isomeric with di-docosahexaenoic (22:6 n-3)
phosphatidylglycerol (di-22:6 PG), a commonly found lipid
that acts as a surfactant in lung tissues [11]. Previously, sepa-
ration and identification of di-22:6-BMP and di-22:6 PG have
required either HPLC or ion mobility–based separations [12,
13].
In order to measure the spatial distribution of all these mol-
ecules, multiple polarities would be needed. Further, in order
to confirm both their identity and spatial location, a combina-
tion of mass spectrometry (MS) and tandem MS modalities is
required. This could be achieved by analysing multiple tissue
sections, but this then presents additional registration chal-
lenges, as tissues will show changes in structures between
sections, particularly in areas such as tumour microenviron-
ments, or in lung tissues, which are prone to tears and defor-
mation in the sectioning process. After analysis by MSI, there
is often still a significant portion of tissue remaining; there-
fore, a much better route to gain the information neededwould
be by repeat analysis of the same tissue section. Repeat anal-
ysis of a single section by MSI was used by Eberlin et al. to
analyse proteins and lipids from a single tissue section [14]. In
their methods, DESI was first used to acquire images of lipids,
followed by MALDI for protein analysis. More recently,
Steven et al. performed repeat analysis of a single section by
MALDI MSI to acquire data from a single tissue using multi-
ple matrices and to performMS andmultipleMS/MS analyses
[15].
Another means to obtain more information from a sam-
ple by MSI is to perform analyses in both positive and
negative polarities. Thomas et al. showed that using
MALDI matrices that readily ionise molecules in both
positive and negative modes offers coverage of lipids that
cannot be achieved by just one polarity [16]. By
undersampling with the laser, they were able to acquire
images in both polarities from a single section, but at a
compromise of spatial resolution. This has recently been
demonstrated at 25 μm [17] and 10 μm [18] pixel size;
however, this is not possible for DESI MSI due to the
much larger sampling probe size. True dual polarity anal-
ysis can be carried out, but requires custom instrumenta-
tion using two mass analysers [19].
This paper presents multiple repeat analyses of a sin-
gle tissue section by DESI MSI using different polarities
and modalities. These are used to measure the spatial
distribution and confirm the identities of amiodarone, as
well as endogenous and exogenous metabolites from a
single tissue section.
Methods
Chemicals
Methanol (LC-MS grade) was purchased from Fisher
Scientific (Leicestershire, UK); purified water from was pur-
chased from ELGA Purelab Option (Marlow, UK); and raffi-
nose pentahydrate (≥ 98%) and amiodarone hydrochloride (≥
98%) were purchased from Sigma-Aldrich (Dorset, UK) and
used as supplied. Superfrost Plus (Thermo Scientific,
Waltham, MA, USA) glass slides were used for all
experiments.
Animal dosing
Male Wistar Han rats were purchased from Charles River
(Wilmington, MA, USA) at 10–11 weeks old and approxi-
mately 300 g. Inhalation dosing of amiodarone aerosol was
carried out using a capsule-based aerosol generator (CBAG)
mechanism which is a dry powder inhaler (DPI) dosing sys-
tem [20]. Dosing was carried out as follows: on days − 32, a
target dose of 10 mg/kg amiodarone was delivered, and on
days − 2, − 1 and 0, target doses of 30, 10 and 10 mg/kg
amiodarone were delivered over a 30-min period. No adverse
effects were observed with this dose of amiodarone. Animals
were sacrificed on days 1 and 7 according to Animals
(Scientific Procedures) Act 1986 (UK) and European
Directive 2010/63/EU. Control animals were dosed by same
method with air only. Six control and six drug-dosed animals
were used within this study.
Sample preparation
Lungs from dosed and control animals were excised, dissected
into individual lobes and flash frozen in liquid nitrogen.
Sample transport was subsequently carried out on dry ice.
Samples were sectioned at 14 μm using a cryo-microtome
(CM 1850, Leica, Milton Keynes, UK), thaw-mounted onto
glass microscope slides (Superfrost Plus, Thermo Fisher,
Waltham, MA, USA) and stored at − 80 °C until needed.
Prior to use, sectioned samples were transferred immediately
from − 80 °C storage into a vacuum desiccator and left for ~
30 min to warm to room temperature and dry the tissue, thus
minimising condensation on the sample and reducing any fur-
ther metabolic activity. For analysis by DESI, samples were
used with no additional preparation. Three sets of sections
(three slides) were used in total: (A) 16 sections were sampled
via the repeat analysis protocol to provide positive and nega-
tive mode data, (B) 2 sections were sampled in positive mode
MS followed by MS/MS, and (C) 2 sections were sampled in
negative mode MS and MS/MS.
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Mass spectrometry imaging
DESI MSI was carried out using a Waters Xevo G2-XS
Q-ToF instrument with a DESI ion source (both Waters,
UK) with square pixels of either 50 μm for the imaging
MS and MS/MS repeat analysis of the single dosed tissues
or 100 μm for the imaging of all dosing conditions in
positive and negative ion modes. A scan time of 0.48 s
was used in both cases, equating to stage speeds of 100
and 200 μm/s respectively. The mass range was set to
100–1200 for all MS analysis, and for MS/MS, the mass
range was set from 50 to the target mass plus 5. All im-
aging was carried out using a capillary voltage of 4.5 keV
for positive mode and 4.25 keV for negative mode, with a
sampling cone set to 50 a.u. and a source block tempera-
ture of 100 °C. All mass spectrometry was carried out in
sensitivity mode, and MS/MS was performed using
collision-induced dissociation with a collision energy of
35 a.u. and a parent ion resolving quadrupole set to
4.7 a.u. The solvent system used in all cases was 95:5
methanol:water (v:v) with 0.001 mg/mL raffinose added
for use as lock mass compound and internal standard.
Prior to image acquisition, the detected ion intensity from
rhodamine [M+H]+ at m/z 443.23 (from red Sharpie mark-
er pen) for positive ion mode or m/z 666 (unknown ion
from black Staedtler marker pen) for negative ion mode is
checked with a quality control threshold of > 106 required
to carry out the experiment without further optimisation.
Additionally, the characteristics of the eroded spot from
the DESI spray were assessed on a thin film of rhodamine
sublimated onto glass [21]: A tightly focussed, approxi-
mately circular region clearly eroding through the entire
layer in ≤ 1 s is desirable. Different tissue sections were
used for the data in Figs. 1 and 2 a and c. The repeat
analysis was carried out in the following order; for the
positive and negative ion mode comparison, positive ion
mode was carried out first. For the MS and MS/MS im-
aging, MS imaging was carried out first, followed by MS/
MS, and in the case of amiodarone and N-desyl amioda-
rone, amiodarone MS/MS was carried out prior to N-desyl
amiodarone.
Data processing and analysis
Data were converted from proprietary Waters .raw format into
imzML using ProteoWizard [24] and the imzML converter
[25], and imported into MATLAB (version 2017a and statis-
tics and image processing toolbox, The MathWorks, Inc.,
Natick, MA, USA) using SpectralAnalysis [26]. Ion images
were generated by integrating intensities across them/zwidths
specified.
All data were registered using the MATLAB image
processing toolbox (version 2017a image processing
toolbox, The MathWorks, Inc., Natick, MA, USA) ac-
cording to the schematic in Fig. S1 (see Electronic
Supplementary Material, ESM). Firstly, binary masks of
the tissue were created by performing k-means clustering
on the data (k = 2, cosine distance, 3 replicates) [27].
Then, registration points were manually selected using
the MATLAB function “cpselect”. A rigid transformation
was the generated from these selection points using the
positive mode data as the “fixed points”, and negative
mode or MS/MS data as the “moving points”. This trans-
formation was then applied to the full dataset and overlays
of the newly registered ion images were created.
Results and discussion
One of the key advantages of MSI over quantitative
whole-body radiography and LC-MS approaches is the
ability to spatially localise parent drug molecules and its
constituent metabolites. This has been shown to be partic-
ularly important in drug toxicology studies where the drug
and metabolites can have different toxicological effects
and may localise to different tissue areas [28]. Analysing
lung tissue by DESI in positive mode shows ions corre-
sponding to the amiodarone [M+H]+ (m/z 646.04), along
with metabolites previously identified by LC-MS but not
by MSI (N-desyl amiodarone, and metabolites M8 and
M11) [9] which have different spatial distributions (Fig.
1). Amiodarone appears to be highly localised which may
be primarily near major airways as determined by a high-
resolution optical image (ESM Fig. S2) and stained H&E
image (ESM Fig. S3), while the metabolites are much
more homogeneously distributed throughout the tissue.
This can also be seen by analysing the univariate distri-
bution of intensities in boxplots of the intensity in each of
the four images. From these, the amiodarone outliers have
much longer tails (ESM Fig. S4), reflecting the high in-
tensity shown in low pixel numbers for these regions.
However, in MS analysis, even at high mass resolving
power, a number of molecules are detected at the same mea-
sured m/z and if a mass error is introduced, this number in-
creased even further. Therefore, to add confidence to any giv-
en molecular identity, fragmentation and analysis by tandem
MS are required. This has been done previously by bulk mea-
surement using LC-MS/MS [29], although this approach loses
any spatial information, important in cases where multiple
isomeric species are present in different spatial distributions.
This problem is particularly relevant to drug metabolism stud-
ies since manymetabolites have the samemass, but may differ
in their toxicological effects [9]. To confirm the identity of a
molecule and measure the spatial distribution, MS/MS imag-
ing can be performed, and this has been demonstrated for a
variety of different drug molecules [30, 31], although
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additional serial tissue sections would normally be required.
Multiple product ion images from positively charge ions from
the same section have been obtained using multiple reaction
monitoring by Prideaux et al. [32]. To date, there are no re-
ports of full scan and product ion data frommultiple classes of
Fig. 2 Mean MS/MS spectra
from selected regions of interest
from the two biological replicates
of the day 1 dosed tissue of m/z
646 (a) and 662 (b) in positive
mode ionisation, and m/z 865 (C)
in negative mode ionisation. The
images show the distribution of
the major fragment ions of amio-
darone (a) and N-desyl amioda-
rone (b), and the parent ion 865
has two unique distributions with
fragments for BMP(22:6) (m/z
283 and 327) and another ion,
possibly PG 22:6; however, the
MS/MS inclusion window is >
1 Da so other lipids may be in-
cluded into this window. Full im-
age area for a and b is 12.5 ×
9.3 mm, and c is 11.8 × 7.0 mm
Fig. 1 Reference key for the location of the different lung treatments (a),
and selected ion images for example positive and negative mode lipids (b
and c tentatively assigned by mass as PC 32:0 [M+K]+ and PI 38:4 [M
−H]− from literature [22, 23]). Along with amiodarone (d), N-desyl ami-
odarone (e) and metabolites M11 (f) and M8 (g), metabolite M8 has an
isobaric species present which is found in all tissue samples. Full image
area for these data is 46.5 × 23.3 mm
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analyte in positive and negative ion modes from a single
section.
Since lung tissue is particularly fragile, collecting exact
serial sections and alignment of these are exceptionally chal-
lenging. Fixation and embedding following inflation have
been shown to improve tissue handling [33] for lipid analysis
by MSI; however, this workflow is likely to delocalise drug
and metabolite molecules and therefore is not suitable for
spatial distribution studies and more fragile fresh frozen tissue
must be used.
A major advantage of repeat analysis of the same section
multiple times lies in the reduced complexity of registration
routines required for data acquisition. For example, when data
is acquired from serial sections of stable tissues, registration
routines must be devised to account for deformation and
warping of the sample during sectioning [34, 35]. In contrast,
repeat analysis of the same section multiple times means there
is no deformation of the sample and simple rigid registration
routines can be applied to these data. In this study, we used the
MATLAB “cpselect” function to manually define matching
points between data acquired in positive and negative modes
and used these as a basis for rigid transformation using the
MATLAB functions “cp2tform” and “imtransform”. Other
methods such as by normalised cross correlation could be
used; however, the intention was to not introduce any bias into
any further correlation-based analysis by the registration pro-
cess [36].
The approach was demonstrated by analysing two replicate
lung tissue slices taken from a single lung 24 h following
aerosol dosing with 6.25 mg/kg amiodarone. Repeat MS/MS
analysis of the amiodarone [M+H]+ ion (m/z 646) resulted in
known amiodarone fragment peaks (m/z 86.1, 100.1, 201.1
and 572.9) [37, 38] observed with similar apparent spatial
distribution to the parent MS1 images (Fig. 2a). The overlap-
ping spatial distribution is even more apparent when these
images are registered and overlaid with one another
(Fig. 3a). The spatial distribution of amiodarone metabolite
ions was also studied using the same approach. The amioda-
rone metabolite M11 (m/z 662) exists in five possible isomeric
forms (M11-1 to M11-5) with different possible oxidation
locations [9]. The characteristic fragment peaks m/z 201,
116, 100 and 86 were observed, suggesting that the M11-3
andM11-4 molecules are present in these tissues (Figs. 2b and
3b). It is worth noting that the other forms may also still be
present in concentrations that are below the limit of detection.
In this example, these ions had similar spatial distributions to
one another, indicating that they are found within the same
tissue regions, but these methodologies could also be used to
analyse spatial differences in isomeric metabolites which are
not co-localised. Thus, the use of repeat MS/MS analysis in
this manner allows an initial untargeted evaluation of the
identity and spatial location of drugs and their metabolites
in a given tissue, which is a key step forward in drug
discovered and toxicology studies. In addition to being
able to map the spatial location of drug and its metabo-
lites, MSI is also capable of analysing drug-induced
changes to tissues by determining the identity and mea-
suring the spatial distribution of selected endogenous mol-
ecules. Peak-picked mean spectra from both positive and
negative mode analyses were matched to the HMDB da-
tabase using previously described methods [39]. Briefly,
peaks were filtered using a ppm mass error of < 5 and a
C12–C13 isotope image correlation of > 0.7. A large num-
ber of endogenous molecules of interest were tentatively
identified as summarised by Tables S1 and S2 (see ESM).
Since orally administered amiodarone is known to induce
lipidosis in several organs, including the lung, it was
hypothesised that di-22:6-BMP [40] would be detectable in
amiodarone-treated lung tissues [41]. Using MSI analysis, a
mass corresponding to the molecule di-22:6-BMP (detected
nominal mass 865.51: ppm error 8.6554) was observed in
lung slices taken from animals sacrificed 24 h following aero-
sol exposure. The signals were localised to areas surrounding
major airways and appeared similar in spatial distribution to
amiodarone (Fig. 4). The di-22:6-BMP signal appeared to
return to endogenous levels by day 7 following the final ami-
odarone exposure, indicating a resolution to the mild form of
drug-induced lipidosis. Interestingly, conventional histopa-
thology of the lung tissue at all time points following aerosol
dosing with amiodarone did not show lipidosis development
(data not shown), as characterised by visual observation of an
increased number of foamy macrophages containing accumu-
lated lipids. The lack of pronounced lipidosis in the aerosol
dosing model was attributed to a lower concentration of ami-
odarone accumulating in the lung compared with published
oral dosing studies (300 mg/kg) [42]. This discrepancy clearly
demonstrates that modern MS techniques, particularly in this
case with the use of MSI, have pronounced advantages over
conventional histopathology in terms of sensitivity and the
ability to discern the spatial distribution of molecular species
of interest.
Amiodarone and its metabolites are therefore detected in
positive mode as [M+H]+ ions, while di-22:6-BMP is more
easily is commonly detected in negative ion mode as [M−H]−
ions. In order to analyse both these molecules in a single
tissue, serial sections could be taken, but not without the tis-
sues previously discussed.
Fig. 3 Registered RGB overlay images from repeat analysis experiments
including the two biological replicates of the day 1 dosed tissue showing
parent moleculeMS1 (red) andmajorMS/MS fragments (blue and green)
of amiodarone (a), metabolite M11 (b), and di-22:6-BMP or PG di-22:6
(c). Combining positive modeMS1 images of amiodarone andmetabolite
M11 and negative mode images of BMP di-22:6/PG di-22:6 shows the
spatially localised increase in this lipid alongside the presence of drug and
metabolite in the day 1 dosed tissue (d). Full image area for a and b is
12.5 × 9.3 mm, c is 11.8 × 7.0 mm and d is 46.5 × 23.3 mm
Dexter A. et al.8028
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di-22:6-BMP is also an isomer of any PG 44:12 lipid spe-
cies, with many possible lipid side chain combinations.
Therefore, to confirm the exact identity of these lipid species,
it is necessary to fragment these ions and perform tandemMS
experiments. Many of the fragment ions of di-22:6-BMP and
di-22:6 PG are common, since they have the same lipid side
chains; therefore, characterisation would normally require an
orthogonal means of separation [12]. However, by measuring
the spatial distributions of fragments previously reported in
literature to belong specifically to di-22:6-BMP, m/z 283.2
and 327.2 [40], it was observed that these ions were localised
to the same regions, possibly surrounding major airways.
These ions match molecular formulae of C21H31
− (for m/z
283.2) and C22H31O2
− (for m/z 327.2) which could belong
to the 22:6 lipid side chains. Although these side chains
should also be present for PG lipids, these fragment ions had
a very different spatial distribution compared with the parent
m/z 865.5 ion, and since amiodarone is a compound known to
induce lipidosis, and these fragments have previously been
reported for di-22:6-BMP, it is proposed that the fragments
shown correspond to di-22:6-BMP and that spatially resolving
MS/MS fragments can be used to differentiate and confirm a
compounds’ identity.
As stated previously, a major advantage of the repeat anal-
ysis technique is the ability to overlay the images from posi-
tive mode analysis of amiodarone (m/z 646 positive mode),
metabolite M11 (m/z 662 positive mode) and di-22:6-BMP
(m/z 865 negative mode) to show how their spatial distribu-
tions are related to one another (Fig. 3d). These molecules
have then all been confirmed by MS/MS imaging to provide
confidence in their assignment and to visualise their distribu-
tions in the same section. Furthermore, the amiodarone me-
tabolite M11 is known to be forms M11-3 and M11-4 based
on the presence of specific MS/MS fragment peaks.
Conclusions
Repeat analysis of a single tissue section by DESI MSI using
multiple modalities and polarities can provide a wealth of
complimentary information. This can be used to measure the
spatial distribution of drugs and exogenous and endogenous
metabolites all from a single sample, and allows confirmation
of molecular identities. Here we use this methodology to dis-
cover spatially distinct drug-induced lipidosis in lung tissues
after inhaled amiodarone dosing, and regions of lipidosis cor-
relate with regions of high drug and metabolite accumulation.
This is of particular importance for precious or fragile samples
such as lung, where either sample volume or stability pre-
cludes collection of additional serial sections. Currently the
analyses of these data are minimal; however, using these
methodologies, more sophisticated computational and statisti-
cal analyses, such as co-localisation analyses, and image fu-
sion methods could be applied to mine the wealth of data
provided my these multimodal repeat analysis studies. In fur-
ther work, the study of whether repeat analysis may result in
some analytes being delocalised or depleted to different de-
grees by the DESI sampling process will be of interest. We
Fig. 4 Ion image of m/z 865.51 showing a higher distribution of in a
highly localised area of the tissue (possibly major airways) along with a
background in the tissue. This could be the two isomeric species di-22:6-
BMP in the airways and di-22:6 PG throughout the tissue. Full image area
for these data is 46.5 × 23.3 mm
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hypothesise that these will be dependent on the physicochem-
ical properties of the analytes, DESI parameters selected and
solvent composition.
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